120 related articles for article (PubMed ID: 30465366)
41. Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Oz Gul O; Cinkilic N; Gul CB; Cander S; Vatan O; Ersoy C; Yılmaz D; Tuncel E
Mutat Res; 2013 Sep; 757(1):31-5. PubMed ID: 23859957
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
Xu W; Bi Y; Sun Z; Li J; Guo L; Yang T; Wu G; Shi L; Feng Z; Qiu L; Li Q; Guo X; Luo Z; Lu J; Shan Z; Yang W; Ji Q; Yan L; Li H; Yu X; Li S; Zhou Z; Lv X; Liang Z; Lin S; Zeng L; Yan J; Ji L; Weng J
J Intern Med; 2015 Jan; 277(1):137-50. PubMed ID: 25039675
[TBL] [Abstract][Full Text] [Related]
43. Decreased incidence of gout in diabetic patients using pioglitazone.
Niu SW; Chang KT; Lin HY; Kuo IC; Chang YH; Chen YH; Hung CC; Chiu YW; Hwang SJ
Rheumatology (Oxford); 2018 Jan; 57(1):92-99. PubMed ID: 29040733
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
45. The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.
Mori H; Okada Y; Tanaka Y
Intern Med; 2017; 56(11):1301-1306. PubMed ID: 28566590
[TBL] [Abstract][Full Text] [Related]
46. Pioglitazone, Bladder Cancer, and the Presumption of Innocence.
Papaetis GS
Curr Drug Saf; 2022; 17(4):294-318. PubMed ID: 35249505
[TBL] [Abstract][Full Text] [Related]
47. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
48. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
Fabian W; Majkowska L; Stefański A; Moleda P
Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
[TBL] [Abstract][Full Text] [Related]
49. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
Neeser K; Lübben G; Siebert U; Schramm W
Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
[TBL] [Abstract][Full Text] [Related]
50. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
[TBL] [Abstract][Full Text] [Related]
51. Depressive symptoms of type 2 diabetics treated with insulin compared to diabetics taking oral anti-diabetic drugs: a Korean study.
Noh JH; Park JK; Lee HJ; Kwon SK; Lee SH; Park JH; Ko KS; Rhee BD; Lim KH; Kim DJ
Diabetes Res Clin Pract; 2005 Sep; 69(3):243-8. PubMed ID: 16046024
[TBL] [Abstract][Full Text] [Related]
52. Prescribing trend of pioglitazone after safety warning release in Korea.
Jeong HE; Cho SI; Oh IS; Baek YH; Shin JY
Am J Manag Care; 2019 Nov; 25(11):e342-e348. PubMed ID: 31747239
[TBL] [Abstract][Full Text] [Related]
53. Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
Hussain M; Shad MN; Akhtar L
J Pak Med Assoc; 2017 Dec; 67(12):1884-1888. PubMed ID: 29256535
[TBL] [Abstract][Full Text] [Related]
54. Re: Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives Concerning the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
Griebling TL
J Urol; 2019 Jun; 201(6):1033. PubMed ID: 30864908
[No Abstract] [Full Text] [Related]
55. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
Tseng CH
Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
[TBL] [Abstract][Full Text] [Related]
56. Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study.
Gupta S; Gupta K; Ravi R; Mehta V; Banerjee S; Joshi S; Saboo B
Indian J Endocrinol Metab; 2015; 19(5):639-43. PubMed ID: 26425474
[TBL] [Abstract][Full Text] [Related]
57. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.
Song SO; Kim KJ; Lee BW; Kang ES; Cha BS; Lee HC
Diabetes Metab J; 2012 Oct; 36(5):371-8. PubMed ID: 23130322
[TBL] [Abstract][Full Text] [Related]
58. A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
Ripamonti E; Azoulay L; Abrahamowicz M; Platt RW; Suissa S
Diabet Med; 2019 Jan; 36(1):22-35. PubMed ID: 30378165
[TBL] [Abstract][Full Text] [Related]
59. A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone.
Agrawal P; Jain A; Gautam A; Nigam AK; Pursnani N; Farooqui M
Perspect Clin Res; 2021; 12(1):9-13. PubMed ID: 33816203
[TBL] [Abstract][Full Text] [Related]
60. Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review.
Vallabhajosyula S; Vallabhajosyula S; Vallabhajosyula S; Nair S; Kamath A; Rao KN
Med J Armed Forces India; 2016 Jul; 72(3):253-7. PubMed ID: 27546965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
